{
    "url_original": "https://www.wsj.com/articles/merck-eli-lilly-covid-19-treatments-power-quarterly-sales-gains-11643897581?mod=business_lead_pos3",
    "url": "merck-eli-lilly-covid-19-treatments-power-quarterly-sales-gains-11643897581",
    "title": "Merck, Eli Lilly Covid-19 Treatments Power Quarterly Sales Gains",
    "sub_head": "Merck’s new drug has shown promise against Omicron, while regulators have recently curbed use of Lilly’s antibodies",
    "category_1": "Business",
    "time": "2022-02-03 16:25:00",
    "body": "Sales of Covid-19 drugs fueled year-over-year revenue growth for  Merck  & Co. Inc. and  Eli Lilly  & Co. in the last three months of 2021, underscoring the pandemic response’s continued importance for pharmaceutical companies as the public-health crisis enters its third year.<br />Merck’s newly authorized molnupiravir treatment logged sales of $952 million in the fourth quarter, the first period when the drug contributed revenue. Meanwhile, sales of Covid-19 antibodies for Lilly grew by 22% year over year to $1.06 billion, although the company is now facing new restrictions on how they are used against the Omicron variant."
}